dc.description.sponsorship |
We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. CIMBA studies acknowledge the following. BCFR-AU wishes to thank Maggie
Angelakos, Judi Maskiell, Gillian Dite and Helen Tsimiklis. BCFR-NY wishes to
thank members and participants in the New York site of the Breast Cancer
Family Registry for their contributions to the study. BCFR-ON wishes to thank
members and participants in the Ontario Familial Breast Cancer Registry for
their contributions to the study. BFBOCC-LT acknowledges Vilius Rudaitis,
Laimonas Griškevičius, Ramūnas Janavičius. BFBOCC-LV acknowledges Drs.
Janis Eglitis, Anna Krilova and Aivars Stengrevics. BMBSA wishes to thank the
families who contribute to the BMBSA study. BRICOH wishes to thank Yuan
Chun Ding and Linda Steele for their work in participant enrollment and
biospecimen and data management. CNIO wishes to thank Alicia Barroso,
Rosario Alonso and Guillermo Pita for their assistance. The CONSIT TEAM
wishes to thank Maria Grazia Tibiletti of the Ospedale di Circolo-Università
dell’Insubria,Varese, Italy, Giulietta Scuvera of the Fondazione IRCCS Istituto
Nazionale Tumori (INT), Milan, Gabriele Capone of the University of Florence,
Florence, Italy, Alessandra Viel and Riccardo Dolcetti of the CRO Aviano
National Cancer Institute, Aviano, Italy, Aline Martayan of the Istituto
Nazionale Tumori Regina Elena, Rome, Italy, Stefania Tommasi e Brunella
Pilato of the Istituto Nazionale Tumori “Giovanni Paolo II”, Bari, Italy, Liliana
Varesco of the IRCCS, AOU San Martino - IST Istituto Nazionale per la Ricerca
sul Cancro, Genoa, Italy, Laura Cortesi of the University of Modena and
Reggio Emilia, Modena, Italy and Laura Ottini of the University La Sapienza,
Rome, Italy. FCCC thanks Ms. JoEllen Weaver and Dr. Betsy Bove for their
technical support. Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation
Carriers (GEMO) study: National Cancer Genetics Network (UNICANCER
Genetic Group), France. We wish to thank all the GEMO collaborating groups
for their contribution to this study. GEMO Collaborating Centers are:
Coordinating Centres, Unité Mixte de Génétique Constitutionnelle des
Cancers Fréquents, Hospices Civils de Lyon - Centre Léon Bérard & Equipe,
Génétique du cancer du sein, Centre de Recherche en Cancérologie de Lyon:
Olga Sinilnikova†, Sylvie Mazoyer, Francesca Damiola, Laure Barjhoux, Carole
Verny-Pierre, Mélanie Léone, Nadia Boutry-Kryza, Alain Calender, Sophie
Giraud; and Service de Génétique Oncologique, Institut Curie, Paris: Dominique Stoppa-Lyonnet, Marion Gauthier-Villars, Bruno Buecher, Claude
Houdayer, Etienne Rouleau, Lisa Golmard, Agnès Collet, Virginie Moncoutier,
Cédrick Lefol, Muriel Belotti, Antoine de Pauw, Camille Elan, Catherine
Nogues, Emmanuelle Fourme, Anne-Marie Birot. Institut Gustave Roussy,
Villejuif: Brigitte Bressac-de-Paillerets, Olivier Caron, Marine Guillaud-Bataille.
Centre Jean Perrin, Clermont–Ferrand: Yves-Jean Bignon, Nancy Uhrhammer.
Centre Léon Bérard, Lyon: Christine Lasset, Valérie Bonadona, Sandrine
Handallou. Centre François Baclesse, Caen: Agnès Hardouin, Pascaline Berthet,
Dominique Vaur, Laurent Castera. Institut Paoli Calmettes, Marseille: Hagay
Sobol, Violaine Bourdon, Tetsuro Noguchi, Audrey Remenieras, François
Eisinger. CHU Arnaud-de-Villeneuve, Montpellier: Isabelle Coupier, Pascal
Pujol. Centre Oscar Lambret, Lille: Jean-Philippe Peyrat, Joëlle Fournier,
Françoise Révillion, Philippe Vennin†, Claude Adenis. Centre Paul Strauss,
Strasbourg: Danièle Muller, Jean-Pierre Fricker. Institut Bergonié, Bordeaux:
Emmanuelle Barouk-Simonet, Françoise Bonnet, Virginie Bubien, Nicolas
Sevenet, Michel Longy. Institut Claudius Regaud, Toulouse: Christine Toulas,
Rosine Guimbaud, Laurence Gladieff, Viviane Feillel. CHU Grenoble:
Dominique Leroux, Hélène Dreyfus, Christine Rebischung, Magalie Peysselon.
CHU Dijon: Fanny Coron, Laurence Faivre. CHU St-Etienne: Fabienne Prieur,
Marine Lebrun, Caroline Kientz. Hôtel Dieu Centre Hospitalier, Chambéry:
Sandra Fert Ferrer. Centre Antoine Lacassagne, Nice: Marc Frénay. CHU
Limoges: Laurence Vénat-Bouvet. CHU Nantes: Capucine Delnatte. CHU
Bretonneau, Tours: Isabelle Mortemousque. Groupe Hospitalier
Pitié-Salpétrière, Paris: Florence Coulet, Chrystelle Colas, Florent Soubrier,
Mathilde Warcoin. CHU Vandoeuvre-les-Nancy: Johanna Sokolowska, Myriam
Bronner. CHU Besançon: Marie-Agnès Collonge-Rame, Alexandre Damette.
Creighton University, Omaha, USA: Henry T. Lynch, Carrie L. Snyder. G-FAST
wishes to thank the technical support of Ilse Coene en Brecht Crombez.
GOG: this study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank
(CA 27469), the GOG Statistical and Data Center (CA 37517), and the GOG
Cancer Prevention and Control Committee (CA 101165). Drs. Greene, Mai
and Savage were supported by funding from the Intramural Research
Program, NCI. HCSC was supported by a grant RD12/00369/0006 and
12/00539 from ISCIII (Spain), partially supported by European Regional
Development FEDER funds. We acknowledge Alicia Tosar for her technical
assistance. HCSC wishes to thank the technical support of Ilse Coene en
Brecht Crombez. HEBCS would like to thank Dr. Kristiina Aittomäki, Taru A.
Muranen, Drs. Carl Blomqvist and Kirsimari Aaltonen and RNs Irja Erkkilä and
Virpi Palola for their help with the HEBCS data and samples. The Hereditary
Breast and Ovarian Cancer Research Group Netherlands (HEBON) consists of
the following Collaborating Centers: Coordinating center: Netherlands Cancer
Institute, Amsterdam, NL: M.A. Rookus, F.B.L. Hogervorst, F.E. van Leeuwen,
S. Verhoef, M.K. Schmidt, N.S. Russell, J.L. de Lange, R. Wijnands; Erasmus
Medical Center, Rotterdam, NL: J.M. Collée, A.M.W. van den Ouweland,
M.J. Hooning, C. Seynaeve, C.H.M. van Deurzen, I.M. Obdeijn; Leiden
University Medical Center, NL: C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar,
P. Devilee, T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical
Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht,
NL: M.G.E.M. Ausems, R.B. van der Luijt, C.C. van der Pol; Amsterdam Medical
Center, NL: C.M. Aalfs, T.A.M. van Os; VU University Medical Center,
Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University
Hospital Maastricht, NL: E.B. Gómez-Garcia, M.J. Blok; University Medical
Center Groningen, NL: J.C. Oosterwijk, A.H. van der Hout, M.J. Mourits, G.H. de
Bock; The Netherlands Foundation for the detection of hereditary tumours,
Leiden, NL: H.F. Vasen; The Netherlands Comprehensive Cancer Organization
(IKNL): S. Siesling, J.Verloop; The Dutch Pathology Registry (PALGA): L.I.H.
Overbeek. The HEBON study is supported by the Dutch Cancer Society
grants NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands
Organization of Scientific Research grant NWO 91109024, the Pink Ribbon
grants 110005 and 2014-187.WO76, the BBMRI grant NWO 184.021.007/CP46
and the Transcan grant JTC 2012 Cancer 12-054. HEBON thanks the
registration teams of IKNL and PALGA for part of the data collection. HRBCP
wishes to thank Hong Kong Sanatoriuma and Hospital for their continual support. HUNBOCS wishes to thank the Hungarian Breast and Ovarian Cancer
Study Group members (Janos Papp, Tibor Vaszko, Aniko Bozsik, Timea Pocza,
Judit Franko, Maria Balogh, Gabriella Domokos and Judit Ferenczi,
Department of Molecular Genetics, National Institute of Oncology, Budapest,
Hungary) and the clinicians and patients for their contributions to this study.
HVH wishes to thank the Oncogenetics Group (VHIO), and the High Risk and
Cancer Prevention Unit of the University Hospital Vall d’Hebron. ICO wishes
to thank the ICO Hereditary Cancer Program team led by Dr. Gabriel Capella.
INHERIT would like to thank Dr. Martine Dumont, Martine Tranchant for
sample management and skillful technical assistance. J.S. is Chairholder of
the Canada Research Chair in Oncogenetics. J.S. and P.S. were part of the QC
and Genotyping coordinating group of iCOGS (http://ccge.medschl.cam.ac.
uk/research/consortia/icogs/) (BCAC and CIMBA). IPOBCS wishes to thank
Drs. Ana Peixoto, Catarina Santos, Patrícia Rocha and Pedro Pinto for their
skillful contribution to the study. KCONFAB wishes to thank Heather Thorne,
Eveline Niedermayr, all the kConFab research nurses and staff, the heads and
staff of the Family Cancer Clinics, and the clinical follow up study (which has
received funding from the NHMRC, the National Breast Cancer Foundation,
Cancer Australia, and the National Institute of Health (USA)) for their
contributions to this resource, and the many families who contribute to
kConFab. The Modifier Study of Quantitative Effects on Disease (MODSQUAD)
acknowledges ModSQuaD members Csilla Szabo (National Human Genome
Research Institute, National Institutes of Health, Bethesda, MD, USA); Lenka
Foretova and Eva Machackova (Department of Cancer Epidemiology and
Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech
Republic) and Michal Zikan, Petr Pohlreich and Zdenek Kleibl (Oncogynecologic
Center and Department of Biochemistry and Experimental Oncology, First
Faculty of Medicine, Charles University, Prague, Czech Republic). MSKCC wishes
to thank Anne Lincoln and Lauren Jacobs. NICCC wishes to thank the NICCC
National Familial Cancer Consultation Service team led by Sara Dishon, the
laboratory team led by Dr. Flavio Lejbkowicz, and the research field operations
team led by Dr. Mila Pinchev. NRG Oncology thanks the investigators of the
Australia New Zealand NRG Oncology group. OCGN wishes to thank members
and participants in the Ontario Cancer Genetics Network for their contributions
to the study. SEABASS would like to thank Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBrCa Study for assistance in patient
recruitment, data collection and sample preparation. In addition, we thank
Philip Iau, Sng Jen-Hwei and Sharifah Nor Akmal for contributing samples from
the Singapore Breast Cancer Study and the HUKM-HKL study respectively. The
Malaysian Breast Cancer Genetic Study is funded by research grants from the
Malaysian Ministry of Science, Technology and Innovation, Ministry of Higher
Education (UM.C/HIR/MOHE/06) and charitable funding from the Cancer
Research Initiatives Foundation. The SMC team wishes to acknowledge the
assistance of the Meirav Comprehensive breast cancer center team at the
Sheba Medical Center for assistance in this study. Swedish scientists
participating as SWE-BRCA collaborators are: Åke Borg, Håkan Olsson, Helena
Jernström, Karin Henriksson, Katja Harbst, Maria Soller and Ulf Kristoffersson from
Lund University and University Hospital; Anna Öfverholm, Margareta Nordling,
Per Karlsson and Zakaria Einbeigi from Gothenburg Sahlgrenska University
Hospital; Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver,
Gisela Barbany Bustinza and Johanna Rantala from Stockholm and Karolinska
University Hospital; Beatrice Melin, Christina Edwinsdotter Ardnor and Monica
Emanuelsson from Umeå University Hospital; Hans Ehrencrona, Maritta
Hellström Pigg and Richard Rosenquist from Uppsala University; and Marie
Stenmark-Askmalm and Sigrun Liedgren from Linköping University Hospital.
UCHICAGO wishes to thank Cecilia Zvocec, Qun Niu, the physicians, genetic
counselors, research nurses and staff of the Cancer Risk Clinic for their
contributions to this resource and the many families who contribute to our
program. UCLA thanks Joyce Seldon, MSGC and Lorna Kwan, MPH, for
assembling the data for this study. UCSF would like to thank Dr. Robert
Nussbaum and the following genetic counselors for participant recruitment:
Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Amie Blanco
and Peggy Conrad, and Ms. Salina Chan for data management. UKFOCR thanks
Paul Pharoah, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and
Eva Wozniak for their contributions towards the UKFOCR. UPENN wishes to
thank the Breast Cancer Research Foundation, Susan G. Komen Foundation for
the cure and Basser Research Center for BRCA. VFCTG wishes to thank Geoffrey
Lindeman, Marion Harris and Martin Delatycki of the Victorian Familial Cancer
Trials Group. VFCTG also thanks Sarah Sawyer and Rebecca Driessen for assembling these data and Ella Thompson for performing all DNA amplification.
Funding was as follows: the work conducted for this project at Vanderbilt
Epidemiology Center is supported in part by NIH grant R37CA070867 and
endowment funds for the Ingram Professorship and Anne Potter Wilson Chair.
BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by
the European Community Seventh Framework Programme under grant
agreement number 223175 (HEALTH-F2–2009-223175) (COGS). Funding for the
iCOGS infrastructure came from the European Community Seventh Framework
Programme under grant agreement number 223175 (HEALTH-F2-2009-223175)
(COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174,
C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565),
the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative
(1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON
initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian
Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast
Cancer, Komen Foundation for the Cure, the Breast Cancer Research
Foundation, and the Ovarian Cancer Research Fund. The Australian Breast
Cancer Family Study (ABCFS) was supported by grant UM1 CA164920 from the
National Cancer Institute (USA). The content of this manuscript does not
necessarily reflect the views or policies of the National Cancer Institute or any of
the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does
mention of trade names, commercial products, or organizations imply
endorsement by the USA Government or the BCFR. The ABCFS was also
supported by the National Health and Medical Research Council of Australia,
the New South Wales Cancer Council, the Victorian Health Promotion
Foundation (Australia) and the Victorian Breast Cancer Research Consortium.
J.L.H. is a National Health and Medical Research Council (NHMRC) Australia
Fellow and a Victorian Breast Cancer Research Consortium Group Leader. M.C.S.
is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research
Consortium Group Leader. The ABCS study was supported by the Dutch Cancer
Society (grants NKI 2007-3839; 2009 4363); BBMRI-NL, which is a research
infrastructure financed by the Dutch government (NWO 184.021.007); and the
Dutch National Genomics Initiative. The Australian Breast Cancer Tissue Bank is
generously supported by the National Health and Medical Research Council of
Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. The ACP study is funded by the Breast Cancer Research Trust, UK. The work of
the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breakthrough Breast
Cancer and acknowledges NHS funding to the NIHR Biomedical Research
Centre, and the National Cancer Research Network (NCRN). ES is supported by
NIHR Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS
Foundation Trust in partnership with King’s College London, UK. IT is supported
by the Oxford Biomedical Research Centre. BOCS is supported by funds from
Cancer Research UK (C8620/A8372 and C8620/A8857), a US Military Acquisition
(ACQ) Activity, Era of Hope Award (W81XWH-05-1-0204) and the Institute of
Cancer Research (UK). C.T. is funded by a Medical Research Council (UK) Clinical
Research Fellowship. BOCS acknowledges NHS funding to the Royal Marsden/
Institute of Cancer Research NIHR Specialist Cancer Biomedical Research Centre.
The BSUCH study was supported by the Dietmar-Hopp Foundation, the
Helmholtz Society and the German Cancer Research Center (DKFZ). The CECILE
study was funded by Fondation de France, Institut National du Cancer (INCa),
Ligue Nationale contre le Cancer, Ligue contre le Cancer Grand Ouest, Agence
Nationale de Sécurité Sanitaire (ANSES) and Agence Nationale de la Recherche
(ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise
Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The
CNIO-BCS was supported by the Instituto de Salud Carlos III, the Red Temática
de Investigación Cooperativa en Cáncer and grants from the Asociación
Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI11/
00923 and PI12/00070). The CTS was initially supported by the California Breast
Cancer Act of 1993 and the California Breast Cancer Research Fund (contract
97-10500) and is currently funded through the National Institutes of Health (R01
CA77398). Collection of cancer incidence data was supported by the California
Department of Public Health as part of the statewide cancer reporting program
mandated by California Health and Safety Code Section 103885. HAC receives
support from the Lon V Smith Foundation (LVS39420). The University of
Westminster curates the DietCompLyf database created by and funded by
Against Breast Cancer Registered Charity No. 1121258. The ESTHER study was
supported by a grant from the Baden Württemberg Ministry of Science,
Research and Arts. Additional cases were recruited in the context of the VERDI
study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The GC-HBOC was supported by Deutsche Krebshilfe (107 352). The
GENICA was funded by the Federal Ministry of Education and Research (BMBF)
Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the
Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ),
Heidelberg, the Institute for Prevention and Occupational Medicine of the
German Social Accident Insurance, Institute of the Ruhr University Bochum
(IPA), Bochum, and the Department of Internal Medicine, Evangelische Kliniken
Bonn gGmbH, and Johanniter Krankenhaus, Bonn, Germany. The GESBC was
supported by the Deutsche Krebshilfe e. V. [70492] and the German Cancer
Research Center (DKFZ). The HABCS study was supported by an intramural
grant from Hannover Medical School. The HEBCS was financially supported by
the Helsinki University Central Hospital Research Fund, Academy of Finland
(266528), the Finnish Cancer Society, The Nordic Cancer Union and the Sigrid
Juselius Foundation. The HERPACC was supported by a Grant-in-Aid for
Scientific Research on Priority Areas from the Ministry of Education, Science,
Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term
Comprehensive 10-Year Strategy for Cancer Control from Ministry of Health,
Labor and Welfare of Japan, by Health and Labor Sciences Research Grants for
Research on Applying Health Technology from the Ministry Health, Labor and
Welfare of Japan, National Cancer Center Research and Development Fund and
Grant form Takeda Health Foundation. The HMBCS was supported by a grant
from the Friends of Hannover Medical School and by the Rudolf Bartling
Foundation. The HUBCS was supported by a grant from the German Federal
Ministry of Research and Education (RUS08/017). Financial support for KARBAC
was provided through the regional agreement on medical training and clinical
research (ALF) between Stockholm County Council and Karolinska Institutet, the
Swedish Cancer Society, The Gustav V Jubilee foundation and and Bert von
Kantzows foundation. The KBCP was financially supported by the special
Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund
of North Savo, the Finnish Cancer Organizations and strategic funding of the
University of Eastern Finland. kConFab is supported by a grant from the
National Breast Cancer Foundation, and previously by the National Health and Medical Research Council (NHMRC), the Queensland Cancer Fund, the Cancer
Councils of New South Wales, Victoria, Tasmania and South Australia, and the
Cancer Foundation of Western Australia. Financial support for the AOCS was
provided by the United States Army Medical Research and Materiel Command
(DAMD17-01-1-0729), Cancer Council Victoria, Queensland Cancer Fund, Cancer
Council New South Wales, Cancer Council South Australia, The Cancer Foundation of Western Australia, Cancer Council Tasmania and the National
Health and Medical Research Council of Australia (NHMRC; 400413, 400281,
199600). G.C.T. and P.W. are supported by the NHMRC. RB was a Cancer Institute
NSW Clinical Research Fellow. LAABC is supported by grants (1RB-0287, 3 PB-
0102, 5 PB-0018, 10 PB-0098) from the California Breast Cancer Research
Program. Incident breast cancer cases were collected by the USC Cancer
Surveillance Program (CSP) which is supported under subcontract by the
California Department of Health. The CSP is also part of the National Cancer
Institute Division of Cancer Prevention and Control Surveillance, Epidemiology,
and End Results Program, under contract number N01CN25403. LMBC is
supported by the Stichting tegen Kanker (232-2008 and 196-2010). Diether
Lambrechts is supported by the FWO and the KULPFV/10/016-SymBioSysII.
The MARIE study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I,
106332, 108253, 108419), the Hamburg Cancer Society, the German Cancer
Research Center (DKFZ) and the Federal Ministry of Education and Research
(BMBF) Germany (01KH0402). MBCSG is supported by grants from the Italian
Association for Cancer Research (AIRC) and by funds from the Italian citizens
who allocated the 5/1000 share of their tax payment in support of the
Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws
(INT-Institutional strategic projects “5x1000”). The MCBCS was supported by the
NIH grants CA128978, CA116167, CA176785 an NIH Specialized Program of
Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer
Research Foundation and a generous gift from the David F. and Margaret T.
Grohne Family Foundation and the Ting Tsung and Wei Fong Chao
Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer
Council Victoria. The MCCS was further supported by Australian NHMRC grants
209057, 251553 and 504711 and by infrastructure provided by Cancer Council
Victoria. Cases and their vital status were ascertained through the Victorian
Cancer Registry (VCR). The MEC was supported by NIH grants CA63464,
CA54281, CA098758 and CA132839. MSKCC is supported by grants from the
Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical
Cancer Genetics Initiative. The work of MTLGEBCS was supported by the
Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research
for the CIHR Team in Familial Risks of Breast Cancer program, grant number
CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade, grant number PSR-SIIRI-701. MYBRCA is funded by research grants from
the Malaysian Ministry of Science, Technology and Innovation (MOSTI),
Malaysian Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer
Research Initiatives Foundation (CARIF). Additional controls were recruited by
the Singapore Eye Research Institute, which was supported by a grant from the
Biomedical Research Council (BMRC08/1/35/19/550), Singapore and the
National medical Research Council, Singapore (NMRC/CG/SERI/2010). The NBCS
has received funding from the K.G. Jebsen Centre for Breast Cancer Research,
the Research Council of Norway grant 193387/V50 (to A-L Børresen-Dale and
V.N. Kristensen) and grant 193387/H10 (to A-L Børresen-Dale and V.N. Kristensen),
South Eastern Norway Health Authority (grant 39346 to A-L Børresen-Dale) and
the Norwegian Cancer Society (to A-L Børresen-Dale and V.N. Kristensen). The
NBHS was supported by NIH grant R01CA100374. Biological sample preparation
was conducted using the Survey and Biospecimen Shared Resource, which is
supported by P30 CA68485. The Northern California Breast Cancer Family
Registry (NC-BCFR) was supported by grant UM1 CA164920 from the National
Cancer Institute (USA). The content of this manuscript does not necessarily
reflect the views or policies of the National Cancer Institute or any of the
collaborating centres in the Breast Cancer Family Registry (BCFR), nor does
mention of trade names, commercial products, or organizations imply
endorsement by the USA Government or the BCFR. The NHS was funded by
NIH grant CA87969. The OBCS was supported by research grants from the
Finnish Cancer Foundation, the Academy of Finland (grant number 250083,
122715 and Center of Excellence grant number 251314), the Finnish Cancer
Foundation, the Sigrid Juselius Foundation, the University of Oulu, the University
of Oulu Support Foundation and the special Governmental EVO funds for Oulu
University Hospital-based research activities. The Ontario Familial Breast Cancer
Registry (OFBCR) was supported by grant UM1 CA164920 from the National
Cancer Institute (USA). The content of this manuscript does not necessarily
reflect the views or policies of the National Cancer Institute or any of the
collaborating centres in the Breast Cancer Family Registry (BCFR), nor does
mention of trade names, commercial products, or organizations imply
endorsement by the USA Government or the BCFR. The ORIGO study was
supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking
and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS
was funded by Intramural Research Funds of the National Cancer Institute Department of Health and Human Services, USA. The pKARMA study was
supported by Märit and Hans Rausings Initiative Against Breast Cancer. The
RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK
2009-4318). The SASBAC study was supported by funding from the Agency for
Science, Technology and Research of Singapore (A*STAR), the US National
Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation.
The SBCGS was supported primarily by NIH grants R01CA64277, R01CA148667
and R37CA70867. Biological sample preparation was conducted using the
Survey and Biospecimen Shared Resource, which is supported by P30 CA68485.
The scientific development and funding of this project were, in part, supported
by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network
U19 CA148065. The SBCS was supported by Yorkshire Cancer Research S295,
S299, S305PA and Sheffield Experimental Cancer Medicine Centre. The SCCS is
supported by a grant from the National Institutes of Health (R01 CA092447).
Data on SCCS cancer cases used in this publication were provided by the
Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY;
Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer
Data System; North Carolina Central Cancer Registry, North Carolina Division of
Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor
Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry;
Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of
Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas
Central Cancer Registry is fully funded by a grant from National Program of
Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on
SCCS cancer cases from Mississippi were collected by the Mississippi Cancer
Registry which participates in the National Program of Cancer Registries (NPCR)
of the Centers for Disease Control and Prevention (CDC). The contents of this
publication are solely the responsibility of the authors and do not necessarily
represent the official views of the CDC or the Mississippi Cancer Registry.
SEARCH is funded by a programme grant from Cancer Research UK (C490/
A10124) and supported by the UK National Institute for Health Research
Biomedical Research Centre at the University of Cambridge. SEBCS was
supported by the BRL (Basic Research Laboratory) programme through the
National Research Foundation of Korea funded by the Ministry of Education,
Science and Technology (2012-0000347). SGBCC is funded by the NUS start-up Grant, National University Cancer Institute Singapore (NCIS) Centre Grant and
the NMRC Clinician Scientist Award. Additional controls were recruited by the
Singapore Consortium of Cohort Studies-Multi-ethnic cohort (SCCS-MEC), which
was funded by the Biomedical Research Council, grant number 05/1/21/19/425.
SKKDKFZS is supported by the DKFZ. The SZBCS was supported by grant
PBZ_KBN_122/P05/2004. The TBCS was funded by The National Cancer Institute
Thailand. The TNBCC was supported by a Specialized Program of Research
Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer
Research Foundation, a generous gift from the David F. and Margaret T. Grohne
Family Foundation, the Stefanie Spielman Breast Cancer fund and the OSU
Comprehensive Cancer Center, the Hellenic Cooperative Oncology Group
research grant (HR R_BG/04) and the Greek General Secretary for Research and
Technology (GSRT) Program, Research Excellence II, the European Union
(European Social Fund – ESF), and Greek national funds through the
Operational Program “Education and Lifelong Learning” of the National
Strategic Reference Framework (NSRF) - ARISTEIA. The TWBCS is supported by
the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia
Sinica, Taiwan. The UCIBCS component of this research was supported by the
NIH (CA58860, CA92044) and the Lon V Smith Foundation (LVS39420). The
UKBGS is funded by Breakthrough Breast Cancer and the Institute of Cancer
Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical
Research Centre. The US3SS study was supported by Massachusetts (K.M.E.,
R01CA47305), Wisconsin (P.A.N., R01 CA47147) and New Hampshire (L.T.-E.,
R01CA69664) centres, and Intramural Research Funds of the National Cancer
Institute, Department of Health and Human Services, USA. The USRT study was
funded by the Intramural Research Program of the Division of Cancer
Epidemiology and Genetics, National Cancer Institute, National Institutes of
Health, U.S. Department of Health and Human Services. Support for CIMBA
studies: BCFR was supported by grant UM1 CA164920 from the National Cancer
Institute. The content of this manuscript does not necessarily reflect the views
or policies of the National Cancer Institute or any of the collaborating
centers in the Breast Cancer Family Registry (BCFR), nor does mention of
trade names and commercial products, or organizations imply endorsement by
the US Government or the BCFR. BFBOCC is partly supported by Lithuania
(BFBOCC-LT), Research Council of Lithuania grant LIG-07/2012; BIDMC is supported by the Breast Cancer Research Foundation. BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants
from the Cancer Association of South Africa (CANSA) to Elizabeth J. van
Rensburg; SLN was partially supported by the Morris and Horowitz Families
Endowed Professorship. The CBCS was supported by the NEYE Foundation.
CNIO was partially supported by Spanish Association against Cancer (AECC08),
RTICC 06/0020/1060, FISPI08/1120, Mutua Madrileña Foundation (FMMA) and
SAF2010-20493. City of Hope Clinical Cancer Genetics Community Network and
the Hereditary Cancer Research Registry, supported in part by Award Number
RC4CA153828 (PI: J. Weitzel) from the National Cancer Institute and the Office
of the Director, National Institutes of Health. The content is solely the
responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health. Funds for CONSIT TEAM were from
Italian citizens who allocated the 5x1000 share of their tax payment in support
of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws
(INT-Institutional strategic projects ‘5x1000’) to SM and from FiorGen Foundation
for Pharmacogenomics to LP. The CIMBA data management and data analysis
were supported by Cancer Research UK grants C12292/A11174 and C1287/
A10118. SH is supported by an NHMRC Program Grant to GCT. ACA is a Cancer
Research UK Senior Cancer Research Fellow. GCT is an NHMRC Senior Principal
Research Fellow. The DEMOKRITOS has been co-financed by the European
Union (European Social Fund - ESF) and Greek national funds through the
Operational Program “Education and Lifelong Learning” of the National
Strategic Reference Framework (NSRF) - Research Funding Program of the
General Secretariat for Research & Technology: SYN11_10_19 NBCA. Investing in
knowledge society through the European Social Fund. The DKFZ study was
supported by the DKFZ. EMBRACE is supported by Cancer Research UK Grants
C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are
supported by an NIHR grant to the Biomedical Research Centre, Manchester.
The Investigators at The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust are supported by an NIHR grant to the Biomedical
Research Centre at The Institute of Cancer Research and The Royal Marsden
NHS Foundation Trust. Ros Eeles and Elizabeth Bancroft are supported by
Cancer Research UK Grant C5047/A8385. Ros Eelses is also supported by NIHR
support to the Biomedical Research Centre at The Institute of Cancer Research
and The Royal Marsden NHS Foundation Trust. FCCC was supported by The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience
Authority Eminent Scholar Program. A.K.G. was funded by 5U01CA113916,
R01CA140323, and by the Chancellors Distinguished Chair in Biomedical
Sciences Professorship. The German Consortium of Hereditary Breast and
Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no
109076, Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne
(CMMC). The GEMO study was supported by the Ligue Nationale Contre le
Cancer; the Association “Le cancer du sein, parlons-en!” Award; the Canadian
Institutes of Health Research for the “CIHR Team in Familial Risks of Breast
Cancer” program and the French National Institute of Cancer (INCa).
GEORGETOWN (CI) received support from the Non-Therapeutic Subject Registry
Shared Resource at Georgetown University (NIH/NCI grant P30-CA051008), the
Fisher Center for Familial Cancer Research, and Swing For the Cure. Kim De
Leeneer (the G-FAST study) is supported by GOA grant BOF10/GOA/019 (Ghent
University) and spearhead financing of Ghent University Hospital. The HCSC was
supported by a grant RD12/00369/0006 and 12/00539 from ISCIII (Spain),
partially supported by European Regional Development FEDER funds. HEBCS
was financially supported by the Helsinki University Hospital Research Fund,
Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius
Foundation. The HEBON study is supported by the Dutch Cancer Society grants
NKI1998-1854, NKI2004-3088, NKI2007-3756, the Netherlands Organization of
Scientific Research grant NWO 91109024, the Pink Ribbon grant 110005 and the
BBMRI grant NWO 184.021.007/CP46. HEBON thanks the registration teams of
the Comprehensive Cancer Centre Netherlands and Comprehensive Centre
South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology
Registry) for part of the data collection. HRBCP is supported by The Hong Kong
Hereditary Breast Cancer Family Registry and the Dr. Ellen Li Charitable
Foundation, Hong Kong. The Hungarian Breast and Ovarian Cancer Study was
supported by Hungarian Research Grants KTIA-OTKA CK-80745, OTKA K-112228
and the Norwegian EEA Financial Mechanism Hu0115/NA/2008-3/OP-9. ICO:
contract grant sponsor, Asociación Española Contra el Cáncer, Spanish Health
Research Fund; Carlos III Health Institute; Catalan Health Institute and
Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051, RD12/0036/008, PI10/01422, PI10/00748, PI13/00285, PIE13/
00022, 2009SGR290 and 2014SGR364. The IHCC was supported by Grant
PBZ_KBN_122/P05/2004. The ILUH group was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landspitali
University Hospital Research Fund. INHERIT was supported by the Canadian
Institutes of Health Research for the “CIHR Team in Familial Risks of Breast
Cancer” programme, the Canadian Breast Cancer Research Alliance-grant
019511 and the Ministry of Economic Development, Innovation and Export
Trade – grant PSR-SIIRI-701. IOVHBOCS is supported by Ministero della Salute
and “5x1000” Istituto Oncologico Veneto grant. The IPOBCS study was in part
supported by Liga Portuguesa Contra o Cancro. kConFab is supported by a
grant from the National Breast Cancer Foundation, and previously by the
National Health and Medical Research Council (NHMRC), the Queensland
Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and
South Australia, and the Cancer Foundation of Western Australia. KOHBRA is
supported by a grant from the National R&D Program for Cancer Control,
Ministry for Health, Welfare and Family Affairs, Republic of Korea (1020350).
MAYO is supported by NIH grants CA116167, CA128978 and CA176785, an
NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer
(CA116201), a U.S. Department of Defence Ovarian Cancer Idea award
(W81XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a
generous gift from the David F. and Margaret T. Grohne Family Foundation.
Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of
Economic Development, Innovation and Export Trade. MODSQUAD was
supported by MH CZ - DRO (MMCI, 00209805) and by the European Regional
Development Fund and the State Budget of the Czech Republic (RECAMO,
CZ.1.05/2.1.00/03.0101) to LF, and by Charles University in Prague project
UNCE204024 (MZ). MSKCC is supported by grants from the Breast Cancer
Research Foundation, the Robert and Kate Niehaus Clinical Cancer Genetics
Initiative, and the Andrew Sabin Research Fund. NAROD was supported by NIH
grant:1R01 CA149429-01. The research of Drs. MH Greene and PL Mai was
supported by the Intramural Research Program of the US National Cancer
Institute, NIH, and by support services contracts NO2-CP-11019-50 and N02-CP-
65504 with Westat Inc, Rockville, MD. NICCC is supported by Clalit Health
Services in Israel. Some of its activities are supported by the Israel Cancer
Association and the Breast Cancer Research Foundation (BCRF), NY. NNPIO has been supported by the Russian Federation for Basic Research (grants 13-04-
92613, 14-04-93959 and 15-04-01744). NRG Oncology was supported by
National Cancer Institute grants to the NRG Oncology Administrative Office
and Tissue Bank (CA 27469), the NRG Oncology Statistical and Data Center
(CA 37517), and NRG Oncology’s Cancer Prevention and Control Committee
(CA 101165). Drs. Greene, Mai and Savage were supported by funding from the
Intramural Research Program, NCI. OSUCCG is supported by the Ohio State
University Comprehensive Cancer Center. PBCS was supported by the ITT
(Istituto Toscano Tumori) grants 2011-2013. SEABASS was supported by the
Ministry of Science, Technology and Innovation, Ministry of Higher Education
(UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation. SMC was
partially funded through a grant by the Israel cancer association and the
funding for the Israeli Inherited Breast Cancer Consortium. SWE-BRCA
collaborators are supported by the Swedish Cancer Society. UCHICAGO is
supported by NCI Specialized Program of Research Excellence (SPORE) in Breast
Cancer (CA125183), R01 CA142996, 1U01CA161032 and by the Ralph and
Marion Falk Medical Research Trust, the Entertainment Industry Fund National
Women’s Cancer Research Alliance and the Breast Cancer research Foundation.
OIO is an ACS Clinical Research Professor. UCLA was supported by the Jonsson
Comprehensive Cancer Center Foundation, Breast Cancer Research Foundation.
UCSF was supported by the UCSF Cancer Risk Program and Helen Diller Family
Comprehensive Cancer Center. UKFOCR was supported by a project grant from
CRUK to Paul Pharoah. UPENN was supported by National Institutes of Health
(NIH) (R01-CA102776 and R01-CA083855; Breast Cancer Research Foundation;
Susan G. Komen Foundation for the cure, Basser Research Center for BRCA. UPITT/
MWH was supported by the Frieda G. and Saul F. Shapira BRCA-Associated Cancer
Research Program, Hackers for Hope Pittsburgh. Kate Lawrenson is funded by
Ovarian Cancer Research Fund (OCRF) grant number 258807 and an Ann
Schreiber Program of Excellence award from the Ovarian Cancer Research Fund
(POE/USC/01.12). Janet Lee and Howard Shen are funded by National Institute of
Health grant number 5 U19 CA148112-02. Tassja Spindler is funded by National
Institute of Health grant number CA173531-01. Work was performed within the
USC Norris Comprehensive Cancer Center which is supported by a Cancer Center
Support Grant (award number P30 CA014089) from the National Cancer Institute.
VFCTG was supported by the Victorian Cancer Agency, Cancer Australia, National
Breast Cancer Foundation. Dr. Karlan is funded by the American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National
Center for Advancing Translational Sciences (NCATS), Grant UL1TR000124. |
en_ZA |